Hematological AbnormalityHeMATOXNCT03828942
Monitoring the HeMAtological TOXicity of Drugs (HeMATOX)
An observational study of Hematological Abnormality and Hematotoxicity, run by Groupe Hospitalier Pitie-Salpetriere at 2 sites in France.
Trial summary
Several drugs and chemotherapies seem to have an impact on the hematological system. This study investigates reports of hematological toxicities, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematological Abnormality, Hematotoxicity
- What is being tested?
- drug inducing hematological toxicity
- How many people
- 1,000 participants
- Where
- 2 sitesFrance
- Study dates
- 1 Feb 2019to 8 Apr 2023
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients treated with a drug that could be reported in the WHO's pharmacovigilance database
Who may be able to join
- Case reported in the WHO's pharmacovigilance database till 01/02/2019
Who cannot join
- Chronology not compatible between the drug and the toxicity
Trial locations and contacts
2 sites in 1 country.
France2 sites
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM
Paris, 75013
Rhumatology department, CHU Strasbourg, Hautepierre hospital
Strasbourg, 67098
About this study
Official title: Monitoring the HeMAtological TOXicity of Drugs
Several drugs and chemotherapies seem to have an impact on the hematological system. This study investigates reports of hematological toxicities, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Read the detailed description
Several drugs and chemotherapies seem to have an impact on the hematological system and are responsible of a wide range of hematological side effects. Those are poorly described, due to the modification of the pharmacopeia, and the recent recognition of several of these adverse events. This study investigates the main characteristics of patients affected by rare hematological side effects imputed to drugs. A causality assessment according to the WHO-UMC (World Health Organization - Uppsala Monitoring Center) is systematically applied.
- Conditions
- Hematological Abnormality, Hematotoxicity
- Being tested
- drug inducing hematological toxicity
- Keywords
- advrese event, hematotoxicity, drugs, chemotherapies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
drug inducing hematological toxicityDrug
Drugs susceptible to induce hematological toxicities
| Study group | Role | What they receive |
|---|---|---|
| Hematological toxicity induced by drugs and chemotherapies | Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity Receives: Drug: drug inducing hematological toxicity |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hematological toxicities of drugs Identification and report of cases of hematological toxicities associated with drugs.
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Secondary outcomes (7)
Causality assessment of reported hematological toxicities events according to the WHO system
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Description of the type of hematological toxicity depending on the category of drug
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Description of the other immune related adverse events concomitant to the hematological toxicity induced by drugs
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Description of the duration of treatment when the toxicity happens (role of cumulative dose)
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Description of the drug-drug interactions associated with adverse events
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Description of the pathologies (cancer) for which the incriminated drugs have been prescribed
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Description of the population of patients having hematological toxicity adverse event
Case reported in the World Health Organization (WHO) database of individual safety case reports
Measured: to 01/02/2019
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2019
- Study start1 Feb 2019
- Primary completion1 Feb 2022
- Study completion8 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematological AbnormalityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 1,000 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Groupe Hospitalier Pitie-Salpetriere
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joe Elie Salem, Groupe Hospitalier Pitie-Salpetriere
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03828942
- Sponsor's protocol ID
- CIC1421-19-01
- Acronym
- HeMATOX
- Status last verified
- Apr 2023
- First submitted
- 1 Feb 2019
- Last updated
- 13 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monitoring the HeMAtological TOXicity of Drugs
- ClinicalTrials.gov ID
- NCT03828942
- Acronym / sponsor ID
- HeMATOX / CIC1421-19-01
- Conditions
- Hematological Abnormality, Hematotoxicity
- Keywords
- advrese event, hematotoxicity, drugs, chemotherapies
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Groupe Hospitalier Pitie-SalpetriereUniversity, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France
- Study start
- 1 Feb 2019 (actual)
- Primary completion
- 1 Feb 2022 (actual)
- Study completion
- 8 Apr 2023 (actual)
- First posted
- 4 Feb 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Several drugs and chemotherapies seem to have an impact on the hematological system. This study investigates reports of hematological toxicities, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Detailed description
Several drugs and chemotherapies seem to have an impact on the hematological system and are responsible of a wide range of hematological side effects. Those are poorly described, due to the modification of the pharmacopeia, and the recent recognition of several of these adverse events. This study investigates the main characteristics of patients affected by rare hematological side effects imputed to drugs. A causality assessment according to the WHO-UMC (World Health Organization - Uppsala Monitoring Center) is systematically applied.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hematological toxicity induced by drugs and chemotherapies | – | Drug: drug inducing hematological toxicityCase reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients treated with a drug that could be reported in the WHO's pharmacovigilance database
Key inclusion criteria (1 listed)
- Case reported in the WHO's pharmacovigilance database till 01/02/2019
Key exclusion criteria (1 listed)
- Chronology not compatible between the drug and the toxicity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| drug inducing hematological toxicityDrugs susceptible to induce hematological toxicities | Drug | Hematological toxicity induced by drugs and chemotherapies |
Primary outcome
Hematological toxicities of drugs Identification and report of cases of hematological toxicities associated with drugs.
Time frame: to 01/02/2019
Case reported in the World Health Organization (WHO) database of individual safety case reports
7 secondary outcomes
Causality assessment of reported hematological toxicities events according to the WHO system
Time frame: to 01/02/2019
Description of the type of hematological toxicity depending on the category of drug
Time frame: to 01/02/2019
Description of the other immune related adverse events concomitant to the hematological toxicity induced by drugs
Time frame: to 01/02/2019
Description of the duration of treatment when the toxicity happens (role of cumulative dose)
Time frame: to 01/02/2019
Description of the drug-drug interactions associated with adverse events
Time frame: to 01/02/2019
Description of the pathologies (cancer) for which the incriminated drugs have been prescribed
Time frame: to 01/02/2019
Description of the population of patients having hematological toxicity adverse event
Time frame: to 01/02/2019
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Hematological Abnormality
RecruitingPhase 2
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Hematologic Malignancy, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematological Abnormality and Hematotoxicity, run by Groupe Hospitalier Pitie-Salpetriere at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hematological toxicities of drugs Identification and report of cases of hematological toxicities associated with drugs. (time frame: to 01/02/2019). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2023.